Search
Clinician Ordering Portal
Scientific Evidence
23-gene expression profile (GEP) testing for diagnosis of cutaneous melanocytic lesions in a Medicare-eligible population
Mar 2024
The high accuracy and clinical utility of the 23-GEP test demonstrated across multiple prior studies are applicable to the Medicare-eligible population.
Publication: Poster, presented at the 2023 College of American Pathologist (CAP) Annual Meeting
Diagnostic discordance among histopathological reviewers for difficult-to- diagnose melanocytic lesions
Jan 2024
Publication: Poster, presented at the 2024 Winter Clinical Dermatology Conference - Hawaii®, Honolulu, Hawaii, January 12-17, 2024
Diagnostic utility of the 23-gene expression profile test for an atypical intradermal melanocytic proliferation
Dec 2023
A case report describing how MyPath GEP testing leads to diagnostic clarity in a histopathologically ambiguous melanocytic lesion on the face of a 34-year-old man.
Publication: Future Medicine
A Physician’s Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms
Dec 2023
A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.
Publication: Journal of Clinical and Aesthetic Dermatology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms
Nov 2023
Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions
Publication: Skin
An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus
Nov 2023
Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.
Publication: American Journal of Gastroenterology
A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus
Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Publication: Clinical and Translational Gastroenterology
The Tissue Systems Pathology Test Outperforms Pathology Review in Risk-Stratifying Patients with Low-Grade Dysplasia
Nov 2023
This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.
Publication: Gastroenterology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi center performance cohort of cutaneous melanocytic neoplasms
Oct 2023
Publication: Poster, presented at the 2023 ASDP Annual Meeting
A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center
Sep 2023
TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.
Publication: Poster presentation (61) at AFS 2023, Dallas
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort
Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Publication: Diseases of the Esophagus
Asymmetrical pigmented lesion with high clinical suspicion for melanoma
Jun 2023
A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.
